Compare ASPS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | TCRX |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 64.1M |
| IPO Year | N/A | 2021 |
| Metric | ASPS | TCRX |
|---|---|---|
| Price | $6.09 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 26.4K | ★ 526.0K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $169,648,000.00 | $8,423,000.00 |
| Revenue This Year | $38.29 | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $899.06 | ★ N/A |
| Revenue Growth | ★ 10.68 | N/A |
| 52 Week Low | $4.92 | $0.88 |
| 52 Week High | $15.96 | $2.67 |
| Indicator | ASPS | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 54.55 |
| Support Level | $5.55 | $1.09 |
| Resistance Level | $6.06 | $1.21 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 39.66 | 41.57 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.